Dose‐dependent pharmacokinetics and psychomotor effects of caffeine in humans
…, JE Goddard, MM Cotreau… - The Journal of …, 1997 - Wiley Online Library
Twelve healthy volunteers received oral placebo, 250 mg of caffeine, and 500 mg of
caffeine in a randomized, double‐blind, single‐dose crossover study. Caffeine kinetics were …
caffeine in a randomized, double‐blind, single‐dose crossover study. Caffeine kinetics were …
The influence of age and sex on the clearance of cytochrome P450 3A substrates
MM Cotreau, LL von Moltke, DJ Greenblatt - Clinical pharmacokinetics, 2005 - Springer
Cytochrome P450s (CYPs) are an important family of enzymes in the metabolism of many
therapeutic agents and endogenous metabolic reactions. The CYP3A subfamily is especially …
therapeutic agents and endogenous metabolic reactions. The CYP3A subfamily is especially …
Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells
…, U Schwertschlag, AM Slager, MM Cotreau… - The journal of molecular …, 2006 - Elsevier
Ulcerative colitis (UC) and Crohn's disease (CD) are common inflammatory bowel diseases
producing intestinal inflammation and tissue damage. Although emerging evidence …
producing intestinal inflammation and tissue damage. Although emerging evidence …
The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans
MM Cotreau, S Warren, JL Ryan… - The Journal of …, 2003 - Wiley Online Library
A study in healthy male volunteers was completed to evaluate the safety, tolerability, and
pharmacokinetics of a single oral dose of the antiparasitic moxidectin (MOX). This drug is …
pharmacokinetics of a single oral dose of the antiparasitic moxidectin (MOX). This drug is …
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in …
…, MJA de Jonge, P Bhargava, T Isoe, MM Cotreau… - Clinical Cancer …, 2011 - AACR
Purpose: To assess the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety,
pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF …
pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF …
Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway
…, SA Jelinsky, HA Harris, SE Choe, MM Cotreau… - Cancer research, 2009 - AACR
Uterine leiomyomata, or fibroids, are benign tumors of the uterine myometrium that
significantly affect up to 30% of reproductive-age women. Despite being the primary cause of …
significantly affect up to 30% of reproductive-age women. Despite being the primary cause of …
In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat
…, BE Laurijssens, LL Von Moltke, MM Cotreau… - … of Pharmacology and …, 2002 - ASPET
Interactions of midazolam and ketoconazole were studied in vivo and in vitro in rats.
Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous …
Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous …
Fluoxetine impairs clearance of alprazolam but not of clonazepam
…, SH Preskorn, MM Cotreau… - Clinical …, 1992 - Wiley Online Library
Volunteer male subjects received single 1.0 mg oral doses of alprazolam and of clonazepam
on two occasions, during coadministration of 40 mg/day fluoxetine or of placebo. When the …
on two occasions, during coadministration of 40 mg/day fluoxetine or of placebo. When the …
A study of 17β-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy
MM Cotreau, VM Chennathukuzhi, HA Harris, L Han… - Maturitas, 2007 - Elsevier
BACKGROUND: Vaginal atrophy (VA) is a prevalent disorder in postmenopausal women
that is characterized by decreased epithelial thickness, reduced vaginal maturation index (VMI) …
that is characterized by decreased epithelial thickness, reduced vaginal maturation index (VMI) …
Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level
MM Cotreau, LL von Moltke, MC Beinfeld… - … of pharmacological and …, 2000 - Elsevier
Studies were conducted to characterize assays for the isolation and quantitation of rat
cytochrome P450 (CYP) 3A isoforms from hepatic and intestinal tissues. Isolated intestinal …
cytochrome P450 (CYP) 3A isoforms from hepatic and intestinal tissues. Isolated intestinal …